Childhood Onset Fluency Disorder
A speech disorder involving frequent problems with the normal fluency and flow of speech.
Cluster Number:
Wiki Number: W040
Diagnosis: Childhood Onset Developmental Dysfluency
US Patients: 10% Preschoolers
World Patients:
Sex Ratio:
Age Onset: Ages 4-6
Brain Area:
Symptoms: Dysfluencies: stuttering, repetition, mistiming, or poor inflection. Time between toddler and pre-school.
Progression: Children may repeat syllables or words as the try to frame sentences correctly. Fluent speech may be delayed.
Causes:
Medications: None listed – this is normal development, but may be delayed.
Therapies: 10% benefit from a speech therapist/speech language pathologist. They learn how to pronounce speech sounds correctly.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Case Report: Deutetrabenazine as an Adjunctive Treatment for Stutteringby Catherine A Ha on November 11, 2021
Childhood-Onset Fluency Disorder (Stuttering) is a neurodevelopmental disorder in which disturbances occur in the normal fluency and time patterning of speech. While the dopamine system has been well-described in its neurophysiology, there currently is no FDA-approved treatment for stuttering. Second-generation antipsychotics, which have been effective in the treatment of schizophrenia and bipolar disorder, act as dopamine D-2 receptor antagonists at the postsynaptic neuron and have been shown...
- Evaluation of an integrated fluency and Acceptance and Commitment Therapy intervention for adolescents and adults who stutter: Participant perspectivesby Alice K Hart on May 23, 2021
CONCLUSION: Findings support the authenticity, acceptability, and social validity of an integrated fluency and psychosocial intervention for stuttering. Findings also highlight the need for consideration of the consumer voice in the management of stuttering disorders, in keeping with person-centred care.
- Identifying developmental stuttering and associated comorbidities in electronic health records and creating a phenome risk classifierby Dillon G Pruett on April 24, 2021
CONCLUSIONS: This study demonstrates the feasibility of using EHRs in the study of stuttering and found phenotypic associations. The creation of the PheRC has the potential to enable future studies of stuttering using existing EHR data, including investigations into the genetic etiology.
- Investigation of Risperidone Treatment Associated With Enhanced Brain Activity in Patients Who Stutterby Gerald A Maguire on March 1, 2021
Stuttering is a childhood onset fluency disorder that leads to impairment in speech. A randomized, double-blinded placebo-controlled study was conducted with 10 adult subjects to observe the effects of risperidone (a dopamine receptor 2/serotonin receptor 2 antagonist) on brain metabolism, using [^(18)F] deoxyglucose as the marker. At baseline and after 6 weeks of taking risperidone (0.5-2.0 mg/day) or a placebo pill, participants were assigned to a solo reading aloud task for 30 min and...